North America Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Country and Growth Forecast, 2021-2027

The North America Diabetic Retinopathy Market is expected to witness market growth of 10.8% CAGR during the forecast period (2021 2027).

The market is also being driven by an increase in the prevalence of diabetes, a rise in the geriatric population, an increase in the incidence of diabetes-related blindness, and a greater focus on earlier detection to control diseases. In contrast, the advent of combination therapies for the therapeutics of diabetic macular edema, as well as expanding markets in various countries all over the world, are likely to create numerous prospects for the growth of the diabetic retinopathy market over the coming years.

The treatment of diabetic retinopathy is determined by the symptoms, age, and overall health statistics of the patient. It can also be defined by the severity of the ailment. If advanced retinopathy is treated before the retina is significantly damaged, people in advanced stages of retinopathy have a fair chance of retaining their eyesight. The vitreous that occupies the center of the eye is removed during vitrectomy surgery.

According to the Centers for Disease Control and Prevention (CDC), around 100 million Americans have diabetes, which is one of the leading causes of blindness. The regional market is also growing as people become more aware of sophisticated solutions for treating diabetic retinopathy. The diabetic retinopathy market in North America is highly competitive. For example, Bayer AG is a leading pharmaceutical company in the United States that has dominated the market by producing high-quality diabetic retinopathy treatments. As a result, new entrants should weigh the risks of entering into a competitive market. The regional market is also growing because of the favorable reimbursement policies and the rising diabetes prevalence. One of the key factors leading to the huge regional share is the high market penetration of anti-VEGF medications such as Avastin, Elea, and Lucentis.

The US market dominated the North America Diabetic Retinopathy Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $2,103.7 Million by 2027. The Canada market anticipated to grow at a CAGR of 13.3% during (2021 - 2027). Additionally, The Mexico market is expected to display a CAGR of 12.3% during (2021 - 2027).

Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• Proliferative
• Diabetic Macular Edema (DME)

By Treatment Type

• Anti VEGF Drug
• Steroid Implants
• Laser Surgeries
• Vitrectomy

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Allergan PLC (Abbvie, Inc.)
• Bayer AG
• Alimera Sciences, Inc.
• Novartis AG
• Pfizer, Inc.
• F-Hoffmann-La Roche Ltd.
• Ampio Pharmaceuticals-us
• KOWA CO., LTD.
• Regeneron Pharmaceuticals, Inc.
• Bausch Health Companies, Inc.

Unique Offerings from the publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free